ClinicalTrials.gg
Active, not recruitingNCT06506955Updated Jul 28, 2026

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

A Phase 2/3 interventional study of futibatinib and futibatinib, fulvestrant in Advanced/Metastatic Cancer, sponsored by Taiho Oncology, Inc.. Active, not recruiting at 9 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 316 studies in Neoplasm Metastasis with a site in United Kingdom — 43 open to participants now, 86 under way, 38 of them phase 3. Neoplasm Metastasis · United Kingdom.

Planned enrollment
279th of 294
15 · median 208
Started
2024
with 11 others
Phase 2/3
12 of 316
4 open now
Primary completion
2027-04
later than 41 of 85 live
Registered
295th of 316
by date

Among the 316 studies in Neoplasm Metastasis with a site in United Kingdom, this one is the 279th largest by planned enrollment of the 294 interventional ones that give a count, is one of 12 that started in 2024, is one of 12 in phase 2/3, reaches primary completion later than 41 of the 85 other live ones, and was the 295th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

43 of the 316 studies in Neoplasm Metastasis with a site in United Kingdom are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Neoplasm Metastasis with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a nonrandomized, open-label, multicenter rollover study for patients who received futibatinib as monotherapy or as combination therapy in a Taiho-sponsored futibatinib study.

Read the detailed description

TAS-120-404 is a nonrandomized, open-label, multicenter rollover study for patients who received futibatinib as monotherapy or as combination therapy in a Taiho-sponsored futibatinib study.

Patients who are still receiving futibatinib as monotherapy or as combination therapy, are deriving clinical benefit with no undue risk as assessed by the investigator, and have not met any of the antecedent protocol-specific discontinuation criteria are eligible to participate.

03

Conditions studied

  • Advanced/Metastatic Cancer

Keywords

  • Futibatinib
  • TAS-120
  • FGFR
  • Cholangiocarcinoma
  • Breast cance
  • Urothelial Carcinom
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written .
  • Receiving futibatinib as monotherapy or as combination therapy in an antecedent futibatinib study and deriving clinical benefit with no undue risk as assessed by the investigator.
  • Women of (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to receiving treatment. Both males and females of must agree to use effective during study treatment and for a specified time after the last dose of study treatment.
  • Ability to take medications orally (PO) (feeding tube is not permitted).

Exclusion criteria

Exclusion Criteria:

  • Has met any discontinuation criteria within the antecedent futibatinib study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    TAS-120 (futibatinib) monotherapy

    TAS-120 tablets, oral, cycle length is defined as per antecedent study design

    Drug: futibatinib

  • Experimental
    TAS-120 (futibatinib) combination therapy with fulvestrant

    TAS-120 tablets in combination with fulvestrant, oral, cycle length is defined as per antecedent study design

    Drug: futibatinib, fulvestrant

Interventions

  • TAS-120 futibatinib monotherapy

    Also known as: TAS-120

  • Drugfutibatinib, fulvestrant

    Drug pages: Futibatinib · Fulvestrant

    TAS-120 futibatinib combination therapy with fulvestrant

    Also known as: TAS-120 + fulvestrant

06

What researchers measure

Primary outcomes

  1. Number of participants with serious adverse events, treatment-related adverse events, and any AEs leading to treatment discontinuation graded according to NCI-CTCAE v5.0.

    To collect long term safety information in patients continuing to receive treatment with futibatinib as monotherapy or in combination with fulvestrant who participated in a Taiho-sponsored futibatinib study and who are deriving clinical benefit with no undue risk

    Time frame: through study completion, an average of 5 years

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Apr 2027, 30 months after the start.

Of 27 phase 2/3 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 98. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Jul 18, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Apr 30, 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06506955
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Oct 1, 2024
Primary completion
Apr 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Jul 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Futibatinib · Fulvestrant

Start the discussion